MEI Pharma (NASDAQ:MEIP – Free Report) had its price objective trimmed by Stifel Nicolaus from $8.00 to $7.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a hold rating on the stock. MEIP has been the topic of a number of other reports. StockNews.com downgraded shares of […]